Genvor Inc

$ Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000147793223001798 Filed on March 28, 2023

Income Statement

Concept	2023 Q1	2022 Q3	2021 Q4

Balance Sheet

Concept	2023 Q1	2022 Q3	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.510K
YoY Change
Cash & Equivalents	$1.513K	$296.4K	$0.00
Short-Term Investments
Other Short-Term Assets	$15.40K	$2.000K	$0.00
YoY Change
Inventory
Prepaid Expenses		$0.00	$1.331K
Receivables
Other Receivables
Total Short-Term Assets	$16.91K	$298.4K	$536.0K
YoY Change		32.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$16.65K	$17.57K	$18.94K
YoY Change		-9.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$16.65K	$17.57K	-$536.0K
YoY Change		-17.9%
TOTAL ASSETS
Total Short-Term Assets	$16.91K	$298.4K	$536.0K
Total Long-Term Assets	$16.65K	$17.57K	-$536.0K
Total Assets	$33.56K	$316.0K	$0.00
YoY Change		27.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$302.3K	$516.7K	$3.500K
YoY Change	5396.36%	1450.64%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$48.75K
YoY Change
Long-Term Debt Due	$1.162M
YoY Change
Total Short-Term Liabilities	$1.763M	$1.868M	$2.450M
YoY Change	4012.92%	-16.92%
LONG-TERM LIABILITIES
Long-Term Debt	$149.4K
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$149.4K	$89.22K	$344.2K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.763M	$1.868M	$2.450M
Total Long-Term Liabilities	$149.4K	$89.22K	$344.2K
Total Liabilities	$1.913M	$1.957M	$2.794M
YoY Change		-28.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$16.69M	-$16.29M	-$69.74K
YoY Change	20828.96%	44.06%
Common Stock	$18.42K	$38.68K	$26.03K
YoY Change	-7.89%	57.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.879M	-$1.641M	-$32.87K
YoY Change
Total Liabilities & Shareholders Equity	$33.56K	$316.0K	$556.9K
YoY Change		27.86%

Cashflow Statement

Concept	2023 Q1	2022 Q3	2021 Q4

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2222961	usd
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38678155	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26025020	shares
CY2021Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	19705	usd
	dei	Document Type DocumentType	10-K
	dei	Document Annual Report DocumentAnnualReport	true
	dei	Entity Central Index Key EntityCentralIndexKey	0001792941
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Entity Public Float EntityPublicFloat	0	usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	9	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	333-234815
	dei	Entity Registrant Name EntityRegistrantName	GENVOR INCORPORATED
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-2054746
	dei	Entity Address Address Line1 EntityAddressAddressLine1	13155 Noel Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 900
	dei	Entity Address City Or Town EntityAddressCityOrTown	Dallas
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	75240
	dei	City Area Code CityAreaCode	214
	dei	Local Phone Number LocalPhoneNumber	427-1921
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
	dei	Entity Voluntary Filers EntityVoluntaryFilers	Yes
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18122821	shares
	dei	Auditor Firm AuditorFirmId	76
	dei	Auditor Name AuditorName	Turner, Stone & Company, L.L.P.
	dei	Auditor Location AuditorLocation	Dallas, Texas
CY2022Q3	us-gaap	Cash Cash	296385	usd
CY2021Q4	us-gaap	Cash Cash	384621	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1331	usd
CY2022Q3	genvor	Prepaid Cost For Reverse Capitalization PrepaidCostForReverseCapitalization	0	usd
CY2021Q4	genvor	Prepaid Cost For Reverse Capitalization PrepaidCostForReverseCapitalization	150000	usd
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	2000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	0	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	298385	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	535952	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17565	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18939	usd
CY2022Q3	us-gaap	Notes Receivable Related Parties NotesReceivableRelatedParties	0	usd
CY2021Q4	us-gaap	Notes Receivable Related Parties NotesReceivableRelatedParties	2053	usd
CY2022Q3	us-gaap	Assets Assets	315951	usd
CY2021Q4	us-gaap	Assets Assets	556944	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	1052000	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1632250	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	516658	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	571158	usd
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	3846	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	usd
CY2022Q3	genvor	Sba Loan Current SbaLoanCurrent	48750	usd
CY2021Q4	genvor	Sba Loan Current SbaLoanCurrent	0	usd
CY2022Q3	genvor	Usda Crada Liability UsdaCradaLiability	246400	usd
CY2021Q4	genvor	Usda Crada Liability UsdaCradaLiability	246400	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1867654	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2449808	usd
CY2022Q3	genvor	Convertible Notes Payable Net Of Discounts ConvertibleNotesPayableNetOfDiscounts	89221	usd
CY2021Q4	genvor	Convertible Notes Payable Net Of Discounts ConvertibleNotesPayableNetOfDiscounts	0	usd
CY2022Q3	us-gaap	Notes Payable NotesPayable	0	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	344167	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	89221	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	344167	usd
CY2022Q3	us-gaap	Liabilities Liabilities	1956875	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2793975	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	9	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38678155	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26025020	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	38678	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	26025	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	14608815	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9538772	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16288417	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-11801828	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-1640924	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2237031	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	315951	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	556944	usd
	us-gaap	Revenues Revenues	0	usd
CY2021	us-gaap	Revenues Revenues	0	usd
	us-gaap	Professional Fees ProfessionalFees	233153	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	89640	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	120725	usd
CY2021	us-gaap	Labor And Related Expense LaborAndRelatedExpense	390000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	246480	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	226448	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3512500	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1374	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1832	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	196129	usd
CY2021	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	171023	usd
	us-gaap	Operating Expenses OperatingExpenses	4310361	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	3101904	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4310361	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-3101904	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-51117	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-102792	usd
	genvor	Penalties Penalties	-90000	usd
CY2021	genvor	Penalties Penalties	-120000	usd
	genvor	Beneficial Conversion Feature BeneficialConversionFeature	-30111	usd
CY2021	genvor	Beneficial Conversion Feature BeneficialConversionFeature	0	usd
	genvor	Loss On Agromed Acuisition Failure LossOnAgromedAcuisitionFailure	0	usd
CY2021	genvor	Loss On Agromed Acuisition Failure LossOnAgromedAcuisitionFailure	-114828	usd
	genvor	Loss On Settlement Of Liabilities LossOnSettlementOfLiabilities	-5000	usd
CY2021	genvor	Loss On Settlement Of Liabilities LossOnSettlementOfLiabilities	0	usd
	us-gaap	Other Noncash Income Tax Expense OtherNoncashIncomeTaxExpense	176228	usd
CY2021	us-gaap	Other Noncash Income Tax Expense OtherNoncashIncomeTaxExpense	337620	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4486589	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3439524	usd
	genvor	Basic And Diluted Net Loss Per Common Share BasicAndDilutedNetLossPerCommonShare	-0.14
CY2021	genvor	Basic And Diluted Net Loss Per Common Share BasicAndDilutedNetLossPerCommonShare	-0.15
	genvor	Basic And Diluted Weighted Average Common Shares Outstanding BasicAndDilutedWeightedAverageCommonSharesOutstanding	32437505	shares
CY2021	genvor	Basic And Diluted Weighted Average Common Shares Outstanding BasicAndDilutedWeightedAverageCommonSharesOutstanding	22493382	shares
CY2021	genvor	Adjusted Balance Beginning Of Period Amount AdjustedBalanceBeginningOfPeriodAmount	-1557601	usd
CY2021	genvor	Recapitalization Rto Impact RecapitalizationRtoImpact	-32872	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-1590473	usd
CY2021	genvor	Common Stock Issued For Services Amount CommonStockIssuedForServicesAmount	1523012	usd
CY2021	genvor	Exercise Of Options Amount ExerciseOfOptionsAmount	0	usd
CY2021	genvor	Common Stock Issued For Cash Amount CommonStockIssuedForCashAmount	570005	usd
CY2021	genvor	Common Stock Options Issued For Services CommonStockOptionsIssuedForServices	699948	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3439524	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2237031	usd
	genvor	Common Stock Issued For Services Amount CommonStockIssuedForServicesAmount	3512500	usd
	genvor	Common Stock Issued For Cash Amount CommonStockIssuedForCashAmount	165275	usd
	genvor	Common Stock Issued For Debt Conversion Amount CommonStockIssuedForDebtConversionAmount	1235555	usd
	genvor	Founder Shares Issued Amount FounderSharesIssuedAmount	0	usd
	genvor	Payment For Reverses Capitalization PaymentForReversesCapitalization	-150000	usd
	genvor	Issuance Of Common Stock To Prior S1 Investors Amount IssuanceOfCommonStockToPriorS1InvestorsAmount	49725	usd
	genvor	Issuance Of Common Stock For Note Receivable Amount IssuanceOfCommonStockForNoteReceivableAmount	0	usd
	genvor	Issuance Of Common Stock For2021 Spa Amount IssuanceOfCommonStockFor2021SpaAmount	0	usd
	genvor	Issuance Of Common Stock For Settlements Amount IssuanceOfCommonStockForSettlementsAmount	0	usd
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	269916	usd
	genvor	Issuance Of Preferred Stock Amount IssuanceOfPreferredStockAmount	0	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4486589	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-1640924	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4486589	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3439524	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1374	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1832	usd
	genvor	Interest Expense Capitalized Into Notes Payable InterestExpenseCapitalizedIntoNotesPayable	0	usd
CY2021	genvor	Interest Expense Capitalized Into Notes Payable InterestExpenseCapitalizedIntoNotesPayable	10000	usd
	genvor	Late Fee Capitalized Into Notes Payable LateFeeCapitalizedIntoNotesPayable	90000	usd
CY2021	genvor	Late Fee Capitalized Into Notes Payable LateFeeCapitalizedIntoNotesPayable	120000	usd
	genvor	Loss On Agromed Acquisition Failure LossOnAgromedAcquisitionFailure	0	usd
CY2021	genvor	Loss On Agromed Acquisition Failure LossOnAgromedAcquisitionFailure	-114828	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3512500	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2222961	usd
	genvor	Beneficial Conversion Feature Amortization BeneficialConversionFeatureAmortization	-30111	usd
CY2021	genvor	Beneficial Conversion Feature Amortization BeneficialConversionFeatureAmortization	0	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	11667	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-5000	usd
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1331	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1331	usd
	genvor	Prepaid Costs For Reverse Capitalization PrepaidCostsForReverseCapitalization	150000	usd
CY2021	genvor	Prepaid Costs For Reverse Capitalization PrepaidCostsForReverseCapitalization	-100000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-2053	usd
CY2021	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	0	usd
	us-gaap	Securities Borrowed Increase SecuritiesBorrowedIncrease	139138	usd
CY2021	us-gaap	Securities Borrowed Increase SecuritiesBorrowedIncrease	323564	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-3846	usd
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	0	usd
	genvor	Increase Decrease In Usda Crada Liability IncreaseDecreaseInUsdaCradaLiability	0	usd
CY2021	genvor	Increase Decrease In Usda Crada Liability IncreaseDecreaseInUsdaCradaLiability	72800	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-553236	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-663203	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	300000	usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	365000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	6000	usd
	genvor	Repayment Of Receivable From Related Parties RepaymentOfReceivableFromRelatedParties	0	usd
CY2021	genvor	Repayment Of Receivable From Related Parties RepaymentOfReceivableFromRelatedParties	25579	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	165000	usd
CY2021	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	570005	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	usd
CY2021	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-3575	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	465000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	899851	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-88236	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	236648	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	384621	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	147973	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	296385	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	384621	usd
	us-gaap	Interest Paid InterestPaid	0	usd
CY2021	us-gaap	Interest Paid InterestPaid	0	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
	genvor	Discount On Notes Payable DiscountOnNotesPayable	269916	usd
CY2021	genvor	Discount On Notes Payable DiscountOnNotesPayable	35000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	13480	usd
	genvor	Issuance Of Common Stock For Debt Conversion IssuanceOfCommonStockForDebtConversion	1235555	usd
CY2021	genvor	Issuance Of Common Stock For Debt Conversion IssuanceOfCommonStockForDebtConversion	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	49725	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	genvor	Fundraising Services FundraisingServices	170000	usd
CY2021	genvor	Fundraising Services FundraisingServices	0	usd
	genvor	Prepaid Costs For Reverse Capitalization Recognized In Additional Paid In Capital PrepaidCostsForReverseCapitalizationRecognizedInAdditionalPaidInCapital	150000	usd
CY2021	genvor	Prepaid Costs For Reverse Capitalization Recognized In Additional Paid In Capital PrepaidCostsForReverseCapitalizationRecognizedInAdditionalPaidInCapital	0	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16288417	usd
	us-gaap	Profit Loss ProfitLoss	-4486589	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-553236	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
	genvor	Cash Flow Reportingpolicytextblock CashFlowReportingpolicytextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company follows Accounting Standards Codification (“ASC 230”), <em>Statement of Cash Flows</em>, for cash flow reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“indirect method”) as defined by ASC 230, Statement of Cash Flows, to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments.</p>
CY2022Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	46385	usd
	genvor	Fixed Assetspolicytextblock FixedAssetspolicytextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Furniture and equipment are stated at cost. Depreciation is provided by the straight-line method over the useful lives of the related assets, approximately seven years. Expenditures for minor enhancements and maintenance are expensed as incurred.</p>
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	246480	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	226448	usd
	genvor	Stock Based Compensation2policytextblock StockBasedCompensation2policytextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company measures compensation cost for all employee stock-based awards at their fair values on the date of grant. Stock-based awards issued to non-employees are measured at their fair values on the date of grant and are re-measured at each reporting period through their vesting dates, as applicable. The fair value of stock-based awards is recognized as expense over the service period, net of estimated forfeitures, using the straight-line method. </p>
	us-gaap	Dilutive Securities DilutiveSecurities	300000	usd
CY2021	us-gaap	Dilutive Securities DilutiveSecurities	0	usd
CY2022Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1352000	usd
	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	1060000	shares
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	210779	usd
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	1141221	usd
CY2022Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	989000	usd
CY2022Q3	us-gaap	Interest Payable Current InterestPayableCurrent	146946	usd
	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	2316147	shares
	genvor	Loss On Debt Settelment LossOnDebtSettelment	5000	usd
	genvor	Schedule Of Future Maturities Of The Notes Payabletabletextblock ScheduleOfFutureMaturitiesOfTheNotesPayabletabletextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">300,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q3	genvor	Future Maturities Of Notes Payable Year One FutureMaturitiesOfNotesPayableYearOne	12500	usd
CY2022Q3	genvor	Future Maturities Of Notes Payable Year Two FutureMaturitiesOfNotesPayableYearTwo	300000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	141117	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	222792	usd
	genvor	Late Fees LateFees	90000	usd
CY2021	genvor	Late Fees LateFees	120000	usd
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	9	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	569	shares
CY2022Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.50
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	285	usd
CY2022Q2	genvor	Common Stock Cancel CommonStockCancel	18144112	shares
CY2022Q2	genvor	Common Stock Return CommonStockReturn	1855888	shares
CY2022Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2572885	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2343000	usd
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
	genvor	Schedule Of Loss Before Taxes For Fiscal Yeartabletextblock ScheduleOfLossBeforeTaxesForFiscalYeartabletextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> September 30, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> December 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> 2022 </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> 2021 </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Tax expense (benefit) at the statutory rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(204,559 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(255,478 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State income taxes, net of federal income tax benefit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(25,326 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(31,631 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">229,885</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">287,109</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	204559	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	255478	usd
	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	25326	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	31631	usd
	genvor	Valuation Allowance ValuationAllowance	229885	usd
CY2021	genvor	Valuation Allowance ValuationAllowance	287109	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2572885	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2343000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2572885	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2343000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2572885	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2343000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2572885	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2343000	usd
CY2022Q3	us-gaap	Assets Held In Trust AssetsHeldInTrust	19705	usd
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1073388	usd
CY2021	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2810	usd
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	30240	usd
CY2021	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	20094	usd
	genvor	Merger With Old Genvordisclosuretextblock MergerWithOldGenvordisclosuretextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 8 – MERGER WITH OLD GENVOR</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 27, 2022, the Company, formerly known as Allure Worldwide, Inc., Merger Sub, and Old Genvor completed the Acquisition and Merger transaction (Note 1). The transaction was completed pursuant to the Merger Agreement, pursuant to which Merger Sub merged with and into Old Genvor, with Old Genvor continuing as a wholly owned subsidiary of the Company and the surviving corporation in the Merger. Immediately upon completion of the Merger, the former stockholders of Old Genvor stockholders held a majority of the common stock and voting interest of the combined company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the Merger, the Company issued shares of its common stock to Old Genvor stockholders at an exchange ratio of 1:1 (with each share of Old Genvor common stock automatically converted in the merger into the right to receive a share of Company common stock, and a total of 35,261,871 shares of Company common stock issued to Old Genvor’s pre-merger stockholders). Pursuant to the original Acquisition agreement and Merger, the Company’s founding shareholders retained 5% of the Company’s outstanding shares of common stock, or 1,855,888 shares (Note 4). After closing the Acquisition and for a period of two years following commencement of trading of the Company’s common stock, the Company and Old Genvor agreed that the Company will make additional issuances of the Company’s common stock to the founding shareholders to ensure that in the aggregate they maintain their 5% ownership of the Company’s outstanding common stock. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to business combination accounting for reverse acquisitions, the Company accounted for the Merger as a capital transaction (reverse recapitalization) rather than a business combination (or asset acquisition). Since the Company was formerly a special purpose acquisition company (SPAC) with no assets and only expenses related to maintaining its public shell company status, and Old Genvor has cash, other assets, a contract with the USDA (Note 6), and has raised funds from investors, Old Genvor was determined to be the accounting acquirer. Because a reverse recapitalization is equivalent to the issuance of shares by the private operating company for the net monetary assets of the public shell company, the transaction costs incurred by Old Genvor to effect the recapitalization were recognized as a reduction in additional paid-in capital rather than expensed as incurred. The assets and liabilities of Old Genvor were consolidated with the Company at their book value, the equity accounts were retroactively adjusted to reflect the equity of the Company, with a balancing adjustment through the additional paid-in capital account.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company paid $140,000 and $10,000, respectively, in anticipation of closing the Acquisition. The total $150,000 was recognized in additional paid-in capital as of the date of the Merger.</p>
	genvor	Intellectual Propertiesdisclosuretextblock IntellectualPropertiesdisclosuretextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 9 – INTELLECTUAL PROPERTIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company was granted a patent (#11083775) on August 10, 2021 by the United States Patent and Trademark Office. The patent was assigned by the inventors to the Company and The United States of America, as represented by the Secretary of Agriculture.</p>
	genvor	Schedule Of Converted Shares Of Common Stock Of The Company Into Sharestabletextblock ScheduleOfConvertedSharesOfCommonStockOfTheCompanyIntoSharestabletextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Name</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common Shares Exchanged</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Series B</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Issued</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Jaynes Investment LLC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,000,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ACT Holdings LLC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,312,612</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">731,262</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">LASB Family Trust</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,800,112</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">380,012</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Jesse Michael Jaynes</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,767,611</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">476,762</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Bradley White</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,225,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">122,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> PJ Advisory Group </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,500,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">150,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> Total </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">20,605,334</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">2,060,536</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>

Files In Submission

Name	View Source	Status
0001477932-23-001798-index-headers.html	Edgar Link	pending
0001477932-23-001798-index.html	Edgar Link	pending
0001477932-23-001798.txt	Edgar Link	pending
0001477932-23-001798-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
genvor-20220930.xsd	Edgar Link	pending
genvor_10k.htm	Edgar Link	pending
genvor_10kimg1.jpg	Edgar Link	pending
genvor_10kimg3.jpg	Edgar Link	pending
genvor_ex311.htm	Edgar Link	pending
genvor_ex312.htm	Edgar Link	pending
genvor_ex321.htm	Edgar Link	pending
genvor_ex322.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
genvor-20220930_cal.xml	Edgar Link	unprocessable
genvor-20220930_pre.xml	Edgar Link	unprocessable
genvor-20220930_def.xml	Edgar Link	unprocessable
genvor-20220930_lab.xml	Edgar Link	unprocessable
genvor_10k_htm.xml	Edgar Link	completed
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Genvor Inc

2023 Q1 Form 10-K Financial Statement

#000147793223001798 Filed on March 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission